Clinical Trial Update: Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing grazoprevir/elbasvir to boceprevir-based therapy for chronic hepatitis C was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Boceprevir (boceprevir)
• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)
• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 3 | Status: WITHDRAWN